Google
 
Web www.testcompany.com

BioNews: Study protocols to be amended in two small early-phase Prasugrel studies

From: BioSpectrum Asia <bsaedit(*)myciol.com>
Date: Fri, 26 Oct 2007 03:56:54 +0530
To: "Neethi" <Neethi.s(*)testcompany.com>


<http://www.biospectrumAsia.com/images/NewsLetter/top1_left.gif>
October 26, 2007

<http://www.biospectrumAsia.com/images/NewsLetter/top1_big.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/top1_right.gif> 	

<http://www.biospectrumAsia.com/images/NewsLetter/top2_left.gif>
<http://www.biospectrumAsia.com/Home.asp> <http://www.myciol.com/mailblaster/click.asp?nl=3_193440_Oct25&adUrl=htt p://www.systat.com/downloads/?sec=d008>

<http://www.biospectrumAsia.com/images/NewsLetter/top6_right.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/top4_left.gif>

www.biospectrumasia.com <http://www.biospectrumAsia.com/Home.asp>
<http://www.biospectrumAsia.com/images/NewsLetter/top4_right.gif> 	

<http://www.biospectrumAsia.com/images/NewsLetter/top5_left.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/top6_right.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/top5_left.gif>
<http://www.biospectrumAsia.com/Home/Pharma_Home.asp> <http://www.biospectrumAsia.com/Home/Biotech_Home.asp> <http://www.biospectrumAsia.com/Home/Medtech_Home.asp> <http://www.biospectrumAsia.com/images/NewsLetter/top2_big2.gif>

<http://www.biospectrumAsia.com/images/NewsLetter/top2_right.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/top6_left.gif>
Advertisement
<http://www.biospectrumAsia.com/images/NewsLetter/top6_right.gif> 	

<http://www.biospectrumAsia.com/images/NewsLetter/top7_left.gif>
<http://www.myciol.com/mailblaster/click.asp?nl=3_193440_Oct25&adUrl=htt p://www.safcbiosciences.com>
<http://www.biospectrumasia.com/UserFiles/Image/600x60-1.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/top7_right.gif> 	

<http://www.biospectrumAsia.com/images/NewsLetter/top8_left.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/top8_left2.gif> <http://www.biospectrumAsia.com/images/NewsLetter/top8_right.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/top9_left.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/Icon-Today's-news.gif> <http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif> <http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/bul1.gif> Ranbaxy
launches osonase nasal spray in India <http://www.biospectrumAsia.com/Content/251007IND4679.asp?nl=3_193440_Oc t25> <http://www.biospectrumAsia.com/images/Newsletter/arrow1.gif>

Osonase spray treats allergic rhinitis that represents a global health problem and is a precursor for Asthma. It is a common disease affecting at least 10-25% of the population globally and its prevalence is increasing
<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/devider_line1.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/bul1.gif> Rockeby
Avian flu test selected for Canadian trial <http://www.biospectrumAsia.com/Content/251007OTH4681.asp?nl=3_193440_Oc t25> <http://www.biospectrumAsia.com/images/Newsletter/arrow1.gif>

The results of this work will guide CFIA's selection of rapid diagnostic tests for avian influenza surveillance and emergency response
<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/devider_line1.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/bul1.gif> Study
protocols to be amended in two small early-phase Prasugrel studies <http://www.biospectrumAsia.com/Content/251007OTH4680.asp?nl=3_193440_Oc t25> <http://www.biospectrumAsia.com/images/Newsletter/arrow1.gif>

Enrollment of new patients and administration of the study drug in two small prasugrel-related pharmacodynamic clinical trials are being suspended until protocol amendments can be completed and approved
<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/devider_line1.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/bul1.gif> TPG to
invest in Chinese pharmaceutical firm
<http://www.biospectrumAsia.com/Content/251007CHN4686.asp?nl=3_193440_Oc t25> <http://www.biospectrumAsia.com/images/Newsletter/arrow1.gif>

Private equity firm TPG is investing in pharmaceutical-research outsourcing company Shanghai ChemPartner, The Wall Street Journal reported on its Web site on Wednesday, citing unnamed sources

<http://Biospectrumasia.com/Images/NewsLetter/devider_line1.gif>

<http://www.biospectrumasia.com/bs_registration.asp>
<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/devider_line1.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>

Email to Editorial Team <mailto:bsaedit(*)cybermedia.co.in> | Advertise with BioSpectrum <http://www.biospectrumasia.com/output/index.html>

<http://www.cybermedia.co.in>

About BioSpectrum <http://www.biospectrumAsia.com/bs_about.asp> | Contact Us <http://www.biospectrumAsia.com/bs_contact.asp> | Unsubscribe
<http://myciol.com/mailblaster/unsubscribe.asp?user=Neethi.s(*)testcompany .com&nl=BS_Asia_NL>

<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/top9_left2.gif>
MUST READ         
<http://www.biospectrumAsia.com/images/NewsLetter/bul1.gif> Study
protocols to be amended in two small early-phase Prasugrel studies <http://www.biospectrumAsia.com/Content/251007OTH4680.asp?nl=3_193440_Oc t25> <http://www.biospectrumAsia.com/images/Newsletter/arrow1.gif>

Enrollment of new patients and administration of the study drug in two small prasugrel-related pharmacodynamic clinical trials are being suspended until protocol amendments can be completed and approved
<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/devider_line2.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif>

<http://www.biospectrumAsia.com/images/NewsLetter/spacer.gif> 	
	<http://www.sterlinghrconsulting.com>
<http://www.biospectrumasia.com/UserFiles/Image/DDT_148x130.gif> 

<http://www.sterlinghrconsulting.com/>

<http://www.myciol.com/mailblaster/click.asp?nl=3_193440_Oct25&adUrl=htt p://www.selectbiosciences.com/>         

<http://www.biospectrumAsia.com/images/NewsLetter/top9_right.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/bot_left.gif>
<http://www.biospectrumAsia.com/images/NewsLetter/bot_mid.gif> <http://www.biospectrumAsia.com/images/NewsLetter/bot_right.gif>  

<http://www.myciol.com/mailblaster/open.asp?nl=3_193440_Oct25&user=Neeth i.s(*)testcompany.com> Received on Thu Oct 25 2007 - 18:25:27 EDT


Google
  Web www.testcompany.com   
This archive was generated by hypermail 2.2.0.
Internet Marketing